Mary Hobart, PhD | Psychiatrist.com

Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial

Original Research

Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial

February 19, 2025

In this 10-week study, brexpiprazole in combination with sertraline, but not as monotherapy, demonstrated the potential to be a new efficacious treatment for PTSD.

Mary Hobart , Denise Chang , Nanco Hefting , et al

Effects of Brexpiprazole on Functioning in Schizophrenia

Original Research

Effects of Brexpiprazole on Functioning in Schizophrenia

March 1, 2022

Drawing on 4 RCTs and 2 open-label extension studies of brexpiprazole, this analysis looks at the effects of this medication on functioning both in the short term and over...

Mary Hobart , Christoph U. Correll , Stine R. Meehan , et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

May 22, 2018

Finding effective treatment for depressed patients who do not adequately respond to antidepressant medications is a frequent challenge for clinicians. Read this article to learn about the efficacy, safety,...

Robert D. McQuade , Aleksandar Skuban , Mary Hobart , et al

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Robert D. McQuade , Margaretta Nyilas , William H. Carson , et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Robert D. McQuade , Margaretta Nyilas , William H. Carson , et al